1. Home
  2. HCA vs REGN Comparison

HCA vs REGN Comparison

Compare HCA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCA Healthcare Inc.

HCA

HCA Healthcare Inc.

HOLD

Current Price

$470.73

Market Cap

109.1B

Sector

Health Care

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$809.37

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCA
REGN
Founded
1968
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.1B
73.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
HCA
REGN
Price
$470.73
$809.37
Analyst Decision
Buy
Buy
Analyst Count
19
24
Target Price
$472.12
$798.42
AVG Volume (30 Days)
1.1M
824.3K
Earning Date
01-27-2026
01-30-2026
Dividend Yield
0.61%
0.43%
EPS Growth
15.74
2.88
EPS
25.82
41.59
Revenue
$74,372,000,000.00
$14,247,800,000.00
Revenue This Year
$8.35
$1.99
Revenue Next Year
$4.47
$6.68
P/E Ratio
$18.23
$19.53
Revenue Growth
6.82
2.89
52 Week Low
$295.00
$476.49
52 Week High
$520.00
$814.10

Technical Indicators

Market Signals
Indicator
HCA
REGN
Relative Strength Index (RSI) 46.36 68.64
Support Level $462.77 $753.20
Resistance Level $488.61 $779.75
Average True Range (ATR) 9.41 15.80
MACD -0.19 -0.51
Stochastic Oscillator 34.68 93.24

Price Performance

Historical Comparison
HCA
REGN

About HCA HCA Healthcare Inc.

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: